MA26621A1 - Composition pour aerosols pharmaceutiques - Google Patents

Composition pour aerosols pharmaceutiques

Info

Publication number
MA26621A1
MA26621A1 MA25536A MA25536A MA26621A1 MA 26621 A1 MA26621 A1 MA 26621A1 MA 25536 A MA25536 A MA 25536A MA 25536 A MA25536 A MA 25536A MA 26621 A1 MA26621 A1 MA 26621A1
Authority
MA
Morocco
Prior art keywords
composition
pharmaceutical aerosols
aerosols
pharmaceutical
Prior art date
Application number
MA25536A
Other languages
English (en)
Inventor
Llorca Nathalie
Louis Olivier
Cavaillon Pascal
Rosier Patrick
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808152.4A external-priority patent/GB9808152D0/en
Priority claimed from GBGB9814709.3A external-priority patent/GB9814709D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26621A1 publication Critical patent/MA26621A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA25536A 1998-04-18 1999-04-15 Composition pour aerosols pharmaceutiques MA26621A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808152.4A GB9808152D0 (en) 1998-04-18 1998-04-18 Pharmaceutical aerosol formulation
GBGB9814709.3A GB9814709D0 (en) 1998-07-08 1998-07-08 Pharmaceutical aerosol formulation

Publications (1)

Publication Number Publication Date
MA26621A1 true MA26621A1 (fr) 2004-12-20

Family

ID=26313483

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25536A MA26621A1 (fr) 1998-04-18 1999-04-15 Composition pour aerosols pharmaceutiques

Country Status (30)

Country Link
US (1) US7521042B2 (fr)
EP (1) EP1073417B1 (fr)
JP (1) JP2002512183A (fr)
KR (1) KR20010042816A (fr)
CN (1) CN1145478C (fr)
AP (1) AP2000001961A0 (fr)
AR (1) AR018183A1 (fr)
AT (1) ATE228823T1 (fr)
AU (1) AU755066B2 (fr)
BR (1) BR9909736A (fr)
CA (1) CA2328882A1 (fr)
CO (1) CO5021210A1 (fr)
DE (1) DE69904312T2 (fr)
DK (1) DK1073417T3 (fr)
EA (1) EA200000956A1 (fr)
EE (1) EE200000608A (fr)
ES (1) ES2189410T3 (fr)
HR (1) HRP20000689A2 (fr)
HU (1) HUP0101608A2 (fr)
ID (1) ID27887A (fr)
IL (1) IL139087A0 (fr)
IS (1) IS5665A (fr)
MA (1) MA26621A1 (fr)
NO (1) NO20005218L (fr)
NZ (1) NZ507619A (fr)
PE (1) PE20000433A1 (fr)
PL (1) PL343491A1 (fr)
PT (1) PT1073417E (fr)
TR (1) TR200100144T2 (fr)
WO (1) WO1999053901A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
ES2193069T3 (es) 1999-04-14 2003-11-01 Glaxo Group Ltd Formulacion farmaceutica en aerosol.
PT2283817T (pt) † 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
KR20100107083A (ko) * 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN1791386A (zh) * 2003-05-19 2006-06-21 巴克斯特国际公司 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
US7448389B1 (en) 2003-10-10 2008-11-11 Materials Modification, Inc. Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006023460A2 (fr) 2004-08-16 2006-03-02 Theravance, Inc. Composes a activite agoniste pour recepteur ?2 adrenergique et antagoniste pour recepteur muscarinique
RU2007133547A (ru) * 2005-02-10 2009-03-20 Глаксо Груп Лимитед (GB) Способы получения лактозы с использованием методов предварительной сортировки и приготовляемые из нее фармацевтические композиции
WO2008000042A1 (fr) 2006-06-30 2008-01-03 Iceutica Pty Ltd Procédés de préparation de composés biologiquement actifs sous forme de nanoparticules
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
WO2010024898A2 (fr) 2008-08-29 2010-03-04 Lutonix, Inc. Procédés et appareils pour poser un revêtement sur des cathéters à ballonnet
EP3620154A1 (fr) 2009-02-06 2020-03-11 University Of Southern California Compositions thérapeutiques comprenant des monoterpènes
JP5809985B2 (ja) 2009-02-26 2015-11-11 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
SI2453894T1 (sl) 2009-07-15 2016-02-29 Theravance Biopharma R&D Ip, Llc Kristalinična oblika proste baze bifenilne spojine
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
CA2828833C (fr) 2010-03-03 2020-11-03 Neonc Technologies Inc. Compositions pharmaceutiques comprenant des monoterpenes
WO2011155451A1 (fr) 2010-06-08 2011-12-15 学校法人神戸学院 Particule enrobée et procédé pour la production de particule enrobée
WO2012083178A1 (fr) 2010-12-17 2012-06-21 Neo Oncology Inc. Procédés et dispositifs pour l'utilisation d'alcool isoperillylique
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
ES2600928T3 (es) 2010-08-27 2017-02-13 Neonc Technologies Inc. Composiciones farmacéuticas que comprenden derivados de alcohol perilílico
CN102366405A (zh) * 2011-10-21 2012-03-07 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的氟替卡松丙酸酯气雾剂制剂
WO2013128283A2 (fr) 2012-02-28 2013-09-06 Iceutica Holdings Inc. Bvi Compositions pharmaceutiques inhalables
SI2968313T1 (en) 2013-03-15 2018-05-31 Verona Pharma Plc Combination of medicines
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
EP3872069A1 (fr) 2015-02-12 2021-09-01 Neonc Technologies, Inc. Compositions pharmaceutiques comprenant des dérivés d'alcool périllylique
CN106546751A (zh) * 2016-11-16 2017-03-29 广州华弘生物科技有限公司 用于检测oct4蛋白的酶联免疫试剂盒
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
BR112020016074A2 (pt) 2018-02-08 2020-12-08 Neonc Technologies, Inc Métodos de permeabilização da barreira hematoencefálica

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
PT85521B (pt) * 1986-08-11 1990-06-29 Innovata Biomed Ltd Processo para a preparacao de composicoes farmaceuticas que consistem em microcapsulas
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0655237A1 (fr) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Composition d'aerosol medicinal
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
EP0834314B1 (fr) * 1995-06-12 2003-01-15 Ono Pharmaceutical Co., Ltd. Granules contenant du pranlukast, procede de production des granules et procede de reduction de la cohesion du pranlukast
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
AU5806998A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes

Also Published As

Publication number Publication date
WO1999053901A1 (fr) 1999-10-28
ES2189410T3 (es) 2003-07-01
IL139087A0 (en) 2001-11-25
HUP0101608A2 (hu) 2002-03-28
ID27887A (id) 2001-05-03
EP1073417B1 (fr) 2002-12-04
NO20005218D0 (no) 2000-10-17
US7521042B2 (en) 2009-04-21
EE200000608A (et) 2001-08-15
CO5021210A1 (es) 2001-03-27
KR20010042816A (ko) 2001-05-25
AU755066B2 (en) 2002-12-05
DK1073417T3 (da) 2003-03-24
ATE228823T1 (de) 2002-12-15
EP1073417A1 (fr) 2001-02-07
CN1305369A (zh) 2001-07-25
NO20005218L (no) 2000-11-10
EA200000956A1 (ru) 2001-04-23
CN1145478C (zh) 2004-04-14
CA2328882A1 (fr) 1999-10-28
AP2000001961A0 (en) 2000-12-31
TR200100144T2 (tr) 2001-06-21
PE20000433A1 (es) 2000-05-26
DE69904312T2 (de) 2003-10-16
BR9909736A (pt) 2000-12-19
JP2002512183A (ja) 2002-04-23
HRP20000689A2 (en) 2001-02-28
DE69904312D1 (de) 2003-01-16
PT1073417E (pt) 2003-04-30
AU3523199A (en) 1999-11-08
US20030157032A1 (en) 2003-08-21
AR018183A1 (es) 2001-10-31
PL343491A1 (en) 2001-08-27
IS5665A (is) 2000-10-13
NZ507619A (en) 2003-05-30

Similar Documents

Publication Publication Date Title
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
ID27415A (id) Komposisi farmaseutik
FR2775596B1 (fr) Nouvelles compositions pharmaceutiques
FI973518A0 (fi) Farmaseuttinen koostumus piperidinoalkanoliyhdisteille
FI991485L (fi) Uusi farmaseuttinen koostumus
DK1052974T3 (da) Farmaceutisk sammensætning indeholdende epothilon
EA199900373A3 (ru) Фармацевтические композиции
NO20015175L (no) Farmasöytisk sammensetning
DK0920302T3 (da) Farmaceutisk aerosolsammensætning
NO20005913D0 (no) Legemiddelsammensetning
ID29262A (id) Komposisi farmasi
NO20005218L (no) Farmasöytisk aerosolpreparat
ID27201A (id) Komposisi farmasi
ID27150A (id) Sediaan levotiroksin bahan farmasi
ID29294A (id) Komposisi farmasi
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
ID18698A (id) Komposisi farmasi
EE200100281A (et) Analgeetiline ravimkoostis
ID25857A (id) Komposisi farmasi
FI4488U1 (fi) Farmaseuttinen koostumus
FR2779145B1 (fr) Nouvelles compositions pharmaceutiques
ID26215A (id) Komposisi farmasi
ITMI962628A0 (it) Composizione farmaceutica
ID23531A (id) Komposisi farmasi
UA2861S (uk) Форма для виливання супозиторіїв